Mammalian and Cell Therapy manufacturing: pre-clinical to commercial
In the last few years, a significant Pharmaceutical Industry presence has developed in the Tuas Biomedical Park, led by Lonza’s initial trailblazing investment in 2005. As a leader in global custom manufacturing, we have expanded our presence in these growing Asian demographics. The Singapore site part of our worldwide custom manufacturing network provides customers with capacity to successfully develop and commercialize their important products in the global market.
Our Tuas site is a mammalian cell culture manufacturing facility for the contract development and production of biopharmaceutical products, including monoclonal antibodies (mAbs), cellular therapeutics and other recombinant proteins. Our multi-product facility is located in a largely industrial area in western Singapore. We commenced production in cGMP production in early 2011 with bioreactor production systems at 2,000L and 20,000L batch sizes, for both clinical and commercial operation. The site also has process development services for both early phase clinical (such as cell line construction and process development) as well as late phase clinical (such as process characterization and validation).